Werewolf Therapeutics Income Statement (2021-2025) | HOWL

1Y3Y5Y7Y10YAll
Download Data
Income Statement Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025
Revenue & cost
Revenue 4.15M4.97M7.28M4.46M8.08M5.90M1.50M0.74M1.14M0.01M
Operating items
Research & Development 7.26M9.79M13.40M10.95M13.89M13.07M15.86M11.71M9.58M10.84M9.65M12.91M15.27M12.53M15.73M13.12M13.14M11.63M
Selling, General & Administrative 3.69M4.01M4.48M4.42M5.23M4.44M4.60M4.98M4.57M4.31M4.81M5.00M4.83M4.60M4.62M4.87M4.40M4.09M
Operating Expenses 10.96M13.79M17.88M15.37M19.12M17.51M20.46M16.69M14.15M15.15M14.46M17.90M20.10M17.12M20.35M17.99M17.54M15.73M
Operating Income -10.96M-13.79M-17.88M-15.37M-14.97M-12.54M-13.18M-12.22M-6.07M-9.25M-12.96M-17.16M-18.96M-17.12M-20.35M-17.99M-17.54M-15.73M
EBIT -10.96M-13.79M-17.88M-15.37M-14.97M-12.54M-13.18M-12.22M-6.07M-9.25M-12.96M-17.16M-18.96M-17.12M-20.35M-17.99M-17.54M-15.73M
Non-operating items
Interest & Investment Income 0.05M0.05M-0.03M0.04M0.10M0.59M1.18M1.52M1.95M1.97M1.98M1.97M1.79M1.60M1.31M1.00M0.85M0.70M
Other Non Operating Income -0.02M-0.02M-0.02M0.28M0.00M0.07M-1.11M-0.03M-0.01M-0.01M-0.00M1.61M0.10M-0.09M0.17M0.01M
Non Operating Income 0.04M0.04M0.01M0.02M0.38M0.60M1.25M-1.11M0.97M0.97M0.96M0.97M1.71M0.45M-0.05M0.17M-0.44M-0.64M
Net income details
EBT -10.90M-13.74M-17.92M-15.33M-14.88M-11.95M-12.00M-10.88M-5.07M-8.28M-12.00M-16.19M-18.31M-16.77M-20.31M-18.26M-17.99M-16.37M
Profit After Tax -10.92M-13.76M-17.87M-15.34M-14.59M-11.94M-11.93M-11.98M-5.10M-8.29M-12.00M-16.19M-17.25M-16.67M-20.40M-18.09M-17.98M-16.37M
Income from Continuing Operations -10.90M-13.74M-17.92M-15.33M-14.88M-11.95M-12.00M-10.88M-5.07M-8.28M-12.00M-16.19M-18.31M-16.77M-20.31M-18.26M-17.99M-16.37M
Consolidated Net Income -10.90M-13.74M-17.92M-15.33M-14.88M-11.95M-12.00M-10.88M-5.07M-8.28M-12.00M-16.19M-18.31M-16.77M-20.31M-18.26M-17.99M-16.37M
Income towards Parent Company -10.90M-13.74M-17.92M-15.33M-14.88M-11.95M-12.00M-10.88M-5.07M-8.28M-12.00M-16.19M-18.31M-16.77M-20.31M-18.26M-17.99M-16.37M
Preferred Dividend Payments 56.93M
Net Income towards Common Stockholders -67.85M-13.76M-17.87M-15.33M-14.59M-11.94M-11.93M-10.88M-5.07M-8.28M-12.00M-16.19M-18.31M-16.77M-20.31M-18.26M-17.99M-16.37M
Additional items
EPS (Basic) -3.82-0.51-0.97-0.56-0.53-0.40-0.38-0.34-0.14-0.23-0.33-0.39-0.40-0.38-0.47-0.40-0.40-0.36
EPS (Weighted Average and Diluted) -3.82-0.51-0.97-0.56-0.53-0.40-0.38-0.34-0.14-0.23-0.33-0.39-0.43-0.38-0.46-0.40-0.40-0.36
Shares Outstanding (Weighted Average) 1.23M17.75M27.19M18.45M27.39M27.52M29.76M28.86M34.78M35.56M35.65M35.65M41.61M43.52M43.70M43.33M44.83M44.98M45.80M
Shares Outstanding (Diluted Average) 1.23M17.75M27.19M18.45M27.39M27.52M29.76M28.86M34.78M35.56M35.65M35.65M41.61M44.04M43.70M43.86M44.83M44.98M45.80M
EBITDA -10.96M-13.79M-17.88M-15.37M-14.97M-12.54M-13.18M-12.22M-6.07M-9.25M-12.96M-17.16M-18.96M-17.12M-20.35M-17.99M-17.54M-15.73M
Interest Expenses 0.17M0.95M1.00M1.01M1.00M1.14M1.24M1.27M1.26M1.30M1.34M
Shares Outstanding 1.76M27.57M27.57M27.61M27.65M28.46M30.74M31.52M35.34M35.64M35.66M39.11M43.28M44.83M